Stoke Therapeutics Inc (STOK) Stock Price, Quote & News

Company Profile

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, engages in the development of treatments for severe genetic diseases by upregulating protein expression. The company utilizes its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO) approach in developing antisense oligonucleotides (ASOs) to selectively restore protein levels. Its lead product candidates include STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy; and Zorevun...

Industry: Biotechnology

Sector: Healthcare

Phone: 781 430 8200

Website: www.stoketherapeutics.com

Address:

45 Wiggins Avenue, Bedford, United States

FFGarcia Aug. 25 at 3:56 AM

$STOK Weekly chart. Bullish; first predicted major long-term target is 33.

0 · Reply

Chrisq82 Aug. 22 at 6:33 PM

$STOK bring back January 2021 of $70!!!!!

0 · Reply

TylerDurd3n Aug. 21 at 3:31 PM

$STOK

0 · Reply

Doozio Aug. 20 at 9:58 PM

Only an $ARRY of $SHLS think all $STOK s are crashing. 🐒🍌🧠⏰♾️

1 · Reply

Quantumup Aug. 18 at 7:24 PM

BTIG⬇️ $STOK's PT to $28 from $29, reiterated at a Buy and said that the 36-month data for Zorevunersen (STK-001) seems to bury any remaining questions. $UCBJY $UCBJF $JAZZ $BIIB $ACAD $DNLI BTIG said in its note:

0 · Reply

Christyatmond Aug. 18 at 1:16 PM

$STOK have this forever long, 82% gained. Not selling 😁

0 · Reply

Rjinvestments88 Aug. 17 at 9:51 PM

$STOK may take some profits Monday looking to enter lyra therapeutics while it's at its lows has hold rating pt 17 18 at high 8s as I did with stok was fun last few months may still holding small position

1 · Reply

Doozio Aug. 17 at 3:44 PM

Almost like yo getting da $SHLS 👀 ing the $ARRY of $STOK s ready to go up the roger on the DLO during 🐒🍌🧠⏰♾️

0 · Reply

TylerDurd3n Aug. 15 at 7:52 PM

$STOK Now we are talking

0 · Reply

LadsAndGents Aug. 15 at 7:06 PM

$STOK is BO coming Monday ? $SPY $XBI

1 · Reply

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Aug 12, 2025, 4:01 PM EDT - 12 days ago

Stoke Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Updates

Aug 11, 2025, 7:00 AM EDT - 14 days ago

Stoke Therapeutics and Biogen Announce First Patient Dosed in Phase 3 EMPEROR Study of Zorevunersen, a Potential Disease-Modifying Treatment for Dravet Syndrome

BIIB

Aug 7, 2025, 7:00 AM EDT - 18 days ago

Stoke Therapeutics to Host Webcast and Conference Call to Discuss Second Quarter 2025 Business and Financial Updates

Aug 6, 2025, 4:30 PM EDT - 18 days ago

Stoke Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

Jul 16, 2025, 4:30 PM EDT - 5 weeks ago

Stoke Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jul 10, 2025, 7:00 AM EDT - 6 weeks ago

Biogen and Stoke Therapeutics Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

BIIB

Jul 10, 2025, 7:00 AM EDT - 6 weeks ago

Stoke Therapeutics and Biogen Announce Presentation of Data from Studies of Zorevunersen, an Investigational Medicine for Dravet syndrome, at the 16th European Paediatric Neurology Society (EPNS) Congress

BIIB

Jun 15, 2025, 11:27 PM EDT - 2 months ago

Stoke Therapeutics: Impressive Pipeline And Big Backers

May 29, 2025, 7:30 AM EDT - 3 months ago

Stoke Therapeutics to Present at the Jefferies Global Healthcare Conference

May 13, 2025, 7:00 AM EDT - 3 months ago

Stoke Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Updates

Apr 1, 2025, 4:30 PM EDT - 5 months ago

Stoke Therapeutics to Present at the 24th Annual Needham Virtual Healthcare Conference

Mar 18, 2025, 12:56 PM EDT - 5 months ago

Stoke Therapeutics Stock Slips as CEO Steps Down

Mar 18, 2025, 7:00 AM EDT - 5 months ago

Stoke Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Updates

Mar 18, 2025, 6:58 AM EDT - 5 months ago

Stoke Therapeutics Announces CEO Transition

Feb 26, 2025, 4:30 PM EST - 6 months ago

Stoke Therapeutics to Present at Upcoming Investor Conferences in March

Feb 18, 2025, 8:46 AM EST - 6 months ago

Stoke Therapeutics and Biogen in pact for treatment for severe form of childhood epilepsy

BIIB

$Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments$

Feb 18, 2025, 8:00 AM EST - 6 months ago

Biogen and Stoke Therapeutics Enter into Collaboration to Develop and Commercialize Zorevunersen for the Treatment of Dravet Syndrome, a Rare Genetic Epilepsy Associated with Refractory Seizures and Neurodevelopmental Impairments

BIIB

Feb 16, 2025, 2:23 PM EST - 6 months ago

Stoke Therapeutics: A Pivotal Moment For This RNA Pioneer

Jan 8, 2025, 4:30 PM EST - 8 months ago

Stoke Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference

Jan 7, 2025, 7:00 AM EST - 8 months ago

Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

Jan 6, 2025, 4:30 PM EST - 8 months ago

Stoke Therapeutics to Host Webcast to Discuss Successful Global Regulatory Alignment for a Phase 3 Study of Zorevunersen as Potentially the First Disease Modifying Medicine for Dravet Syndrome

Dec 6, 2024, 12:00 PM EST - 9 months ago

Stoke Therapeutics Presents New Open-Label Extension (OLE) Study Data That Further Support the Potential for Zorevunersen as a Disease-Modifying Medicine for the Treatment of Dravet Syndrome

Dec 5, 2024, 8:30 AM EST - 9 months ago

GeneDx to Expand Access to Exome Testing for Pediatric Epilepsy Patients with New Partners

BIIB PRAX WGS

Dec 4, 2024, 7:00 AM EST - 9 months ago

Stoke Therapeutics Receives FDA Breakthrough Therapy Designation for Zorevunersen for the Treatment of Dravet Syndrome

Dec 2, 2024, 8:00 AM EST - 9 months ago

Stoke Therapeutics Announces Plans to Present New Data that Support Zorevunersen as Potentially the First Disease-Modifying Medicine for Dravet Syndrome at the American Epilepsy Society 2024 Annual Meeting

Nov 5, 2024, 7:00 AM EST - 10 months ago

Stoke Therapeutics Reports Third Quarter Financial Results and Provides Business Updates

Sep 10, 2024, 7:00 AM EDT - 1 year ago

Stoke Therapeutics Presents Zorevunersen Data Showing Substantial Reductions in Seizures and Improvements in Multiple Measures of Cognition and Behavior That Support the Potential for Disease Modification in Dravet Syndrome

Sep 7, 2024, 4:03 AM EDT - 1 year ago

Stoke Therapeutics: The First Gene Therapy For Dravet Syndrome

Sep 4, 2024, 8:00 AM EDT - 1 year ago

Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Stoke Therapeutics to Present Encore Data at the 15th European Epilepsy Congress that Demonstrate the Potential for Zorevunersen to be the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

Sep 3, 2024, 8:00 AM EDT - 1 year ago

Stoke Therapeutics to Present at Upcoming Investor Conferences in September

Aug 7, 2024, 7:00 AM EDT - 1 year ago

Stoke Therapeutics Reports Second Quarter Financial Results and Provides Business Updates

Jun 24, 2024, 3:32 AM EDT - 1 year ago

Enerpac Tool Group, Singular Genomics Systems And 3 Stocks To Watch On Monday

EPAC OMIC ITI XAIR

Jun 14, 2024, 12:10 PM EDT - 1 year ago

Stoke Therapeutics' STK-001: A Potential Game-Changer For Dravet Syndrome

Jun 3, 2024, 4:30 PM EDT - 1 year ago

Stoke Therapeutics to Present at Upcoming Investor Conferences in June

May 6, 2024, 7:00 AM EDT - 1 year ago

Stoke Therapeutics Reports First Quarter Financial Results and Provides Business Updates

Apr 29, 2024, 8:00 AM EDT - 1 year ago

Stoke Therapeutics Appoints Thomas Leggett as Chief Financial Officer

Apr 17, 2024, 8:00 AM EDT - 1 year ago

Stoke Therapeutics Appoints Jason Hoitt as Chief Commercial Officer

Apr 4, 2024, 4:30 PM EDT - 1 year ago

Stoke Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

Mar 27, 2024, 11:40 PM EDT - 1 year ago

Stoke Therapeutics Announces Pricing of Upsized $125 Million Public Offering

Mar 26, 2024, 4:07 PM EDT - 1 year ago

Stoke Therapeutics Announces Proposed Public Offering

Mar 25, 2024, 4:01 PM EDT - 1 year ago

Stoke Therapeutics Announces Landmark New Data That Support the Potential for STK-001 to be the First Disease-Modifying Medicine for the Treatment of Patients with Dravet Syndrome

Mar 25, 2024, 4:01 PM EDT - 1 year ago

Stoke Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results

Jan 8, 2024, 8:00 AM EST - 1 year ago

Stoke Therapeutics Highlights Strategic Priorities and Anticipated Milestones for 2024

Jan 4, 2024, 4:30 PM EST - 1 year ago

Stoke Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Dec 1, 2023, 9:00 AM EST - 1 year ago

Stoke Therapeutics Presents Data From Multiple Studies of Children and Adolescents With Dravet Syndrome at the American Epilepsy Society (AES) 2023 Annual Meeting

Nov 21, 2023, 8:00 AM EST - 1 year ago

Stoke Therapeutics to Present Data from the Company's Dravet Syndrome Clinical Program at the American Epilepsy Society 2023 Annual Meeting

Sep 21, 2023, 8:00 AM EDT - 2 years ago

Stoke Therapeutics to Participate in the 2023 Cantor Global Healthcare Conference

FFGarcia Aug. 25 at 3:56 AM

$STOK Weekly chart. Bullish; first predicted major long-term target is 33.

0 · Reply

Chrisq82 Aug. 22 at 6:33 PM

$STOK bring back January 2021 of $70!!!!!

0 · Reply

TylerDurd3n Aug. 21 at 3:31 PM

$STOK

0 · Reply

Doozio Aug. 20 at 9:58 PM

Only an $ARRY of $SHLS think all $STOK s are crashing. 🐒🍌🧠⏰♾️

1 · Reply

Quantumup Aug. 18 at 7:24 PM

0 · Reply

Christyatmond Aug. 18 at 1:16 PM

$STOK have this forever long, 82% gained. Not selling 😁

0 · Reply

Rjinvestments88 Aug. 17 at 9:51 PM

1 · Reply

Doozio Aug. 17 at 3:44 PM

Almost like yo getting da $SHLS 👀 ing the $ARRY of $STOK s ready to go up the roger on the DLO during 🐒🍌🧠⏰♾️

0 · Reply

TylerDurd3n Aug. 15 at 7:52 PM

$STOK Now we are talking

0 · Reply

LadsAndGents Aug. 15 at 7:06 PM

$STOK is BO coming Monday ? $SPY $XBI

1 · Reply

TylerDurd3n Aug. 15 at 3:57 PM

$STOK No turning back now we are on the radar!!

0 · Reply

Doozio Aug. 14 at 7:04 PM

$TNXP just throw some Tito’s in there. N it’s ABSOLUTELY obviously obvious. 🐒🍌🧠⏰♾️ is gonna turn biotech stinks into $STOK s n they going $MLTX.

0 · Reply

Doozio Aug. 14 at 5:34 PM

$XBI $IWM How can it be the start of a real correction wen da 🧠 has official started spreading the 🧠 $STOK s on the $DLO ?? Chop chop huckleberries let’s get NUTX its 🐒🍌🧠⏰♾️

1 · Reply

Doozio Aug. 13 at 9:31 PM

🐑 think it’s later in the cycle n frothy while these $STOK s are caught in the middle of 🐒🍌🧠⏰♾️

0 · Reply

Baba200TradeBot Aug. 13 at 6:01 PM

lowfloatreport.com/ - $STOK ⬆️ 10.05% gap at the bell (14.89 vs 13.53) wasn’t just an opening pop – price ripped to 17.38 (+26.09%) and, more importantly, never revisited overnight lows, trading the entire session ABOVE the pre-market high of 14.93 📈; that behavior screams real demand, with 1.6 M shares (3.51 × AVG vol) hitting early while dip buyers soaked every pullback, keeping this bio-runner a full 14.57 % above its own open and stretching intraday range to 4.21 – that’s 4.5 × ATR (0.94) 🏋️‍♂️.

0 · Reply

Alpha_Ascendant Aug. 13 at 4:01 PM

$STOK Impressive earnings. Up 36% since I last wrote on it: https://seekingalpha.com/article/4795033-stoke-therapeutics-impressive-pipeline-and-big-backers

0 · Reply

DD_investments Aug. 13 at 3:34 PM

$STOK still very under the radar

0 · Reply

Doozio Aug. 13 at 2:33 PM

$XBI 👀 at these biotech $STOK s get in RYTM. $TIL whuts next? 🐒🍌🍌🧠⏰♾️

0 · Reply

iQuicky Aug. 13 at 12:59 PM

$STOK will this fly?

1 · Reply

TylerDurd3n Aug. 12 at 9:56 PM

$STOK

0 · Reply

TylerDurd3n Aug. 12 at 8:20 PM

$STOK Fresh Hot earnings report Beat gang!! Only up from here

0 · Reply

Doozio Aug. 12 at 4:05 PM

$XBI $STOK s stink. Until some Tito’s n $TNXP n they don’t 🐒🍌🧠⏰♾️

0 · Reply

Market Cap	1.07B
Revenue (ttm)	36.56M
Net Income (ttm)	-88.98M
EPS (ttm)	N/A
PE Ratio	23.15
Forward PE	65.60
Profit Margin	-243.38%
Debt to Equity Ratio	0.00

Volume	1,149,700
Avg Vol	783,862
Day's Range	N/A - N/A
Shares Out	54.80M
Stochastic %K	95%
Beta	1.15
Analysts	Strong Sell
Price Target	$23.78